Skip to main content
AI Market Summary
Loading market intelligence...

Niagen Bioscience, Inc. (CDXC) Stock Forecast 2025 - AI Price Prediction & Analysis


Niagen Bioscience, Inc. (CDXC) AI Stock Price Forecast & Investment Analysis

Niagen Bioscience, Inc. Stock Price Chart and Technical Analysis

Loading Niagen Bioscience, Inc. interactive price chart and technical analysis...

Niagen Bioscience, Inc. (CDXC) - Comprehensive Stock Analysis & Investment Research

Deep dive into Niagen Bioscience, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about Niagen Bioscience, Inc., including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For Niagen Bioscience, Inc.: Niagen Bioscience, Inc. operates in the Life Sciences sector, making it an emerging small-cap investment.

Niagen Bioscience, Inc. (Stock Symbol: CDXC) is a leading company in the Life Sciences sector , specifically operating within the Medicinal Chemicals & Botanical Products industry.

The organization employs approximately 125 professionals worldwide .

The company has established itself as an emerging investment opportunity with substantial growth potential.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing Niagen Bioscience, Inc.'s revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Niagen Bioscience, Inc.: With $91M in annual revenue and 1.6% net margin, the company demonstrates developing profitability.

Annual Revenue: $91 million generating a 1.6% net profit margin .

Market Capitalization: $536 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): -78.9% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for Niagen Bioscience, Inc. stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Spearman correlation coefficient shows the statistical relationship between predictions and actual outcomes.

For Niagen Bioscience, Inc.: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Niagen Bioscience, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: Niagen Bioscience, Inc.'s competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For Niagen Bioscience, Inc.: Market positioning analysis based on available financial and operational metrics.

Niagen Bioscience, Inc. strategically competes in the highly dynamic Medicinal Chemicals & Botanical Products marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities .

The company maintains a healthy 61.5% gross margin, indicating strong pricing power and operational efficiency.

Niagen Bioscience, Inc. (CDXC) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Niagen Bioscience, Inc. stock analysis.

Loading Niagen Bioscience, Inc. comprehensive fundamental analysis and insider trading data...

Deep dive into Niagen Bioscience, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Niagen Bioscience, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Niagen Bioscience, Inc.: With a P/E ratio of -666.15, the market sees the stock as potentially undervalued.

P/E Ratio -666.15x
P/B Ratio 11.64x
Market Cap $536M
EPS $0.01
Book Value/Share $0.60
Revenue/Share $0.79
FCF/Share $-0.19
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Niagen Bioscience, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Niagen Bioscience, Inc.: An ROE of -78.9% indicates room for improvement in shareholder value creation.

ROE -78.9%
ROA -45.1%
ROIC -72.5%
Gross Margin 61.5%
Operating Margin 0.5%
Net Margin 1.6%
EBT Margin -39.3%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Niagen Bioscience, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Niagen Bioscience, Inc.: A current ratio of 2.38 indicates strong liquidity.

Current Ratio 2.38x
Quick Ratio 1.45x
D/E Ratio 0.16x
Financial Leverage 2.05x
Interest Coverage -449.0x
Working Capital $16M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Niagen Bioscience, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Niagen Bioscience, Inc.: Free cash flow of $-26M indicates cash challenges that need attention.

Operating Cash Flow $-26M
Free Cash Flow $-26M
FCF/Sales -37.6%
CapEx/Sales 0.6%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Niagen Bioscience, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Niagen Bioscience, Inc.: An asset turnover of 1.15x demonstrates efficient asset utilization.

Asset Turnover 1.15x
Receivables Turnover 12.8x
Inventory Turnover 1.9x
Fixed Assets Turnover 12.6x
Days Sales Outstanding 29 days
Days Inventory 188 days
Payables Period 144 days
Cash Conversion Cycle 73 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Niagen Bioscience, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Niagen Bioscience, Inc.: With annual revenue of $91M, Niagen Bioscience, Inc. represents a smaller but potentially high-growth operation.

Income Statement ($ Millions)
Total Revenue $91M
Net Income $1M
R&D Expense $6M
SG&A Expense $94M
Cost of Goods Sold $7M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 84%
Cash & Short-term Investments 39%
Total Liabilities 51%
Short-term Debt 8%
Accounts Receivable 12%
Inventory 29%
Dividend & Shareholder Information
Shares Outstanding 77M
Growth Metrics (YoY)
EPS Growth 0.2%

Latest Niagen Bioscience, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Niagen Bioscience, Inc. (CDXC) stock price and investment outlook.

Niagen Bioscience, Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Niagen Bioscience, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
AAWH Unlock Forecast - 30 Days FREE Trial $186M x 106.2x
AIBT Unlock Forecast - 30 Days FREE Trial $0M x x
AYRWF Unlock Forecast - 30 Days FREE Trial $0M x 0.0x
BTMD Unlock Forecast - 30 Days FREE Trial $100M 3.5x -3.0x
CBDY Unlock Forecast - 30 Days FREE Trial $1M x x
CFOO Unlock Forecast - 30 Days FREE Trial $13M x x
CGC Unlock Forecast - 30 Days FREE Trial $403M -0.3x 0.8x
CHUC Unlock Forecast - 30 Days FREE Trial $43M 9.9x 13.4x
CRON Unlock Forecast - 30 Days FREE Trial $1252M 34.7x 1.2x
CURLF Unlock Forecast - 30 Days FREE Trial $2790M x 3.2x
CXXIF Unlock Forecast - 30 Days FREE Trial $51M x 1.8x
CYAN Unlock Forecast - 30 Days FREE Trial $3M -0.5x 0.4x
FTLF Unlock Forecast - 30 Days FREE Trial $169M 25.0x 4.0x
GHBWF Unlock Forecast - 30 Days FREE Trial $45M x 0.4x
GLASF Unlock Forecast - 30 Days FREE Trial $694M x 6.0x
GLUC Unlock Forecast - 30 Days FREE Trial $1M x x
HYEX Unlock Forecast - 30 Days FREE Trial $4M 0.2x 0.2x
JUSHF Unlock Forecast - 30 Days FREE Trial $155M x x
MNMD Unlock Forecast - 30 Days FREE Trial $964M -3.1x 7.4x
MRMD Unlock Forecast - 30 Days FREE Trial $42M x 0.8x
MTEX Unlock Forecast - 30 Days FREE Trial $16M 22.5x 2.4x
NAGE Unlock Forecast - 30 Days FREE Trial $519M 25.4x 7.4x
RAJAF Unlock Forecast - 30 Days FREE Trial $1020M x x
RAPH Unlock Forecast - 30 Days FREE Trial $27M x x
SNYR Unlock Forecast - 30 Days FREE Trial $20M 7.9x -2.1x
TCNNF Unlock Forecast - 30 Days FREE Trial $1902M x 1.6x
TCRG Unlock Forecast - 30 Days FREE Trial $45M x x
USNA Unlock Forecast - 30 Days FREE Trial $373M 29.8x 0.7x

Frequently Asked Questions - Niagen Bioscience, Inc. Stock Forecast

How accurate are Niagen Bioscience, Inc. stock predictions?

Our AI model shows a 34% Spearman correlation coefficient for CDXC predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Niagen Bioscience, Inc. stock price forecasts?

Our analysis considers Niagen Bioscience, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Niagen Bioscience, Inc. a good investment in 2025?

Based on our AI analysis, Niagen Bioscience, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Niagen Bioscience, Inc. forecasts updated?

Niagen Bioscience, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Niagen Bioscience, Inc. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Niagen Bioscience, Inc. stock.

My Portfolio

Investment Dashboard

Loading your portfolio...